Reblozyl 75 mg lyophilized powder for injection Images
Generic Name: luspatercept
This medication has been identified as Reblozyl 75 mg lyophilized powder for injection. It is supplied by Celgene Corporation.
Reblozyl is used in the treatment of Myelodysplastic Syndrome; Anemia; Beta Thalassemia and belongs to the drug class miscellaneous erythropoiesis agents. Reblozyl 75 mg lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Reblozyl
- Generic Name
- luspatercept
- Strength
- 75 mg lyophilized powder for injection
- Availability
- Prescription only
- Drug Class
- Miscellaneous erythropoiesis agents
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Celgene Corporation
- National Drug Code (NDC)
- 59572-0775
More about Reblozyl (luspatercept)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous erythropoiesis agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
